• Patchless Transdermal Drug Delivery ... - Ecn5.com ecn5

2
MARCH 2011 • TransDermal
Industry news
Eisai finalizes
Japanese license
agreement
Tokyo, Japan — Eisai finalized an
exclusive license agreement with
Teikoku Seiyaku, which will re -
search, develop, and market a
new transdermal formulation of
Aricept for treatment of Alz -
heimer’s disease in Japan. Eisai
will supply the active pharmaceutical
ingredients for clinical and
nonclinical use.
Prosolus
Pharmaceuticals plans
to relocate
Philadelphia, Pennsylvania,
USA — According to the South
Florida Business Journal, Prosolus
Pharmaceuticals plans to relocate
to Doral, Florida in Miami-Dade
County. The company, only a year
old, has licensed a transdermal
system and wants to develop a
5,000-square-foot manufacturing
and product-development center
there.
Commercial launch of
Prelude is on track
Franklin, Massachusetts, USA —
Echo Therapeutics’ partner, Ferndale
Pharma Group, received
comments from the US FDA on
the 510(k) submission of the Prelude
SkinPrep System that both
companies deemed minor and
consistent with expectations. Echo
anticipates that the planned date
for commercial launch of the product
will remain on track, pending
FDA clearance.
Alcohol Monitoring
Systems files patent suit
Littleton, Colorado, USA — Alco-
hol Monitoring Systems (AMS)
has filed a lawsuit claiming that
BI, Incorporated has infringed
multiple patents with their TAD
(Transdermal Alcohol Detection)
system. AMS manufactures a
trans dermal alcohol monitoring
system, SCRAMx (Secure Continuous
Remote Alcohol Monitor),
which samples a subject’s perspiration
for the purposes of monitoring
alcohol consumption.
Rutgers University
launches center for
dermal research
Piscataway, New Jersey, USA —
On March 3, 2011, the Center for
Dermal Research at Rutgers University
held its inaugural meeting.
Dr Bozena Michniak-Kohn, PhD,
leads the center. The university
created the center to provide professional
networking opportunities
for its paid industrial members
as well as opportunities for
research collaborations with the
Laboratory for Drug Delivery,
which Michniak-Kohn heads.
Skinvisible signs
feasibility agreement
Las Vegas, Nevada, USA — Skinvisible
Pharmaceuticals signed an
agreement with Novartis Pharma
AG to assess the technical feasibility
of a topical formulation of an
undisclosed com pound using its
Invisicare polymer delivery system.
The agreement includes an
option for the two companies to
enter into a future, exclusive licen -
sing agreement that would in -
clude a licensing fee and royalties
based on sales.
Transdel
Pharmaceuticals
explores strategic
alternatives
La Jolla, California, USA —
Transdel Pharmaceuticals is ex -
ploring strategic alternatives
with two investment banks,
Amer ican Med Tech Advisors
and ESC Advisors, a division of
KEMA Partners. These alternatives
could include, but are not
limited to, partnering or other
collaborative agreements, a
merger, equity or debt financing,
or sale of the company.
Actavis voluntarily
recalls transdermal
Fentanyl
Hafnarfirdi, Iceland — Actavis
issued a voluntary recall of 18 lots
of its 25 mcg Fentanyl patch after
finding one defective lot that
caused the medicine to release
too quickly into the bloodstream.
Apogee Technology
resumes OTC trading
Norwood, Massachusetts, USA
— Apogee Technology resumed
trading on the Over-the-Counter
(OTC) board under the symbol
ATCS.OB.
NICE guidance
recommends Exelon
patch
Basel, Switzerland — The Na -
tional Institute for Health and
Clinical Excellence (NICE) guidance
TA1111 recommended
Novar tis Pharmaceuticals UK’s
Exelon transdermal patch as a
cost-effective option for treatment
of mild-to-moderate Alz -
heimer’s disease.
TransPharma changes
name of transdermal
system
Lod, Israel — TransPharma Medical
changed the name of its drug